A 10-day low-dose Dacogen regimen showed a 33% response rate in myelofibrosis patients, with a median response duration of seven months. High prognostic scores, elevated fetal hemoglobin, and reduced ...
SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Eisai Corporation of North America today announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in ...
Patients with myeloproliferative neoplasm (MPN) may benefit from this combination treatment if they are in the accelerated or blast phase of the disease. Results from a phase 2 study demonstrated that ...
MINNEAPOLIS--(BUSINESS WIRE)--Aug. 1, 2006--MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that the European Medicines Agency (EMEA) ...
DUBLIN, Calif.--(BUSINESS WIRE)-- SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released ...
WOODCLIFF LAKE, N.J., July 1, 2008 Eisai Corporation ofNorth America today announced the preliminary efficacy data from a trialinitiated in 2002 comparing Dacogen(R) (decitabine) to Best Supportive ...
Otsuka has acquired rights from Eisai Inc. to develop and sell in the US, Canada and Japan the DNA methylation inhibitor Dacogen ®. In addition, Otsuka has acquired licensing rights worldwide, ...
With approval of Dacogen (decitabine), the injectable drug for myelodysplastic syndromes from MGI Pharma Inc. and SuperGen Inc. expected May 15, analysts continue to weigh the compound’s chances ...
DUBLIN, Calif.--(BUSINESS WIRE)-- Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), today announced the pre-publication notice of the Food and Drug Administration (FDA), Oncologic Drugs Advisory Committee ...
Most news items about Astex Pharmaceuticals (NAS: ASTX) focus on the company's profitable drug Dacogen. However, on Monday the company announced movement in its pipeline beyond Dacogen. A phase 1 ...
MGI Pharma and SuperGen have won approval in the USA for Dacogen, a new drug for the treatment of patients with myelodysplastic syndromes, a group of bone marrow diseases that can progress to acute ...
Merrill Lynch upgraded MGI Pharma to "buy" from "neutral" with a $32 price target, saying the biopharmaceutical firm's Dacogen cancer drug has a 70% to 80% chance of regulatory approval in September. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results